Welcome to our dedicated page for Addus Homecare SEC filings (Ticker: ADUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicaid reimbursement shifts, caregiver wage pressures, and a steady stream of tuck-in acquisitions make Addus HomeCare Corp’s SEC disclosures a must-read for healthcare investors. Yet tracking every 8-K acquisition notice or isolating state-by-state revenue in a 300-page 10-K can be daunting.
Stock Titan’s AI-powered platform turns those challenges into a clear road map. Need the latest Addus HomeCare quarterly earnings report 10-Q filing? We tag each table so you can jump straight to personal-care margins. Curious about Addus HomeCare insider trading Form 4 transactions? Real-time alerts flag executive stock moves within minutes of EDGAR posting. Our summaries translate complex reimbursement footnotes and hospice census metrics into plain language, offering understanding Addus HomeCare SEC documents with AI instead of hours of manual review.
Here’s how professionals use the page:
- Scan the annual report—Addus HomeCare annual report 10-K simplified—to see how changes in state budgets may affect revenue.
- Compare sequential labor-cost trends in each earnings report filing analysis.
- Monitor Addus HomeCare 8-K material events explained for newly closed acquisitions or reimbursement rate updates.
- Track Addus HomeCare executive stock transactions Form 4 to gauge insider sentiment before guidance shifts.
From proxy statement executive compensation details to Form 4 insider transactions real-time, every filing is indexed, summarized, and refreshed the moment it hits EDGAR. Complex disclosures become actionable insights—so you can focus on decisions, not page counts.
Addus HomeCare Corporation (ADUS) reported the voting results from its 18 June 2025 Annual Meeting of Stockholders in an 8-K filing (Item 5.07).
- Quorum: 17,431,919 shares (94.7% of the 18,399,139 shares outstanding) were represented.
- Director elections: Class I nominees Esteban López, M.D. (93.2% support), Jean Rush (95.2% support) and Susan T. Weaver, M.D. (91.5% support) were elected for terms expiring in 2028. Broker non-votes totaled 875,876 for each nominee.
- Auditor ratification: PricewaterhouseCoopers LLP was re-appointed with 17,369,357 votes for (99.7%), 59,873 against and 2,689 abstentions.
- Say-on-Pay: Executive compensation received 15,216,859 votes for (92.0%), 1,330,522 against and 8,662 abstentions.
- Say-on-Pay frequency: An annual vote was favored by 15,903,154 shares (92.9%), compared with 632,362 for triennial, 3,984 for biennial and 16,543 abstentions. No broker non-votes.
- Board response: The Board will continue to hold the advisory Say-on-Pay vote annually until the next required frequency vote.
The filing contains no financial performance data, strategic transactions or changes to previously reported guidance. All proposals were approved by wide margins, indicating solid shareholder support for governance, compensation and audit practices.
Sinclair, Inc. (SBGI) – Insider Transaction Summary
On 20 June 2025 Sinclair, Inc. filed a Form 4 reporting that director Daniel C. Keith acquired 18,084 shares of the company’s Class A common stock on 06 June 2025. The transaction was coded “A,” indicating an acquisition, and the accompanying footnote clarifies that the shares were issued pursuant to the company’s Stock Incentive Plan.
As a result of this grant, Mr. Keith’s direct beneficial ownership increased to 67,027 shares. No dispositions, derivative security exercises, or indirect holdings were disclosed in the filing, and no transaction price was stated. The Form 4 was signed by Anastasia Thomas Nardangeli, Esq. under a Power of Attorney on Mr. Keith’s behalf.
Because the filing shows additional equity awarded to a sitting director, it may be viewed as a modest affirmation of long-term alignment between the board and shareholders. However, the absence of valuation details or performance conditions limits immediate assessment of the grant’s economic impact.
Addus HomeCare (NASDAQ:ADUS) filed a Form 4 reporting that non-employee director Esteban Lopez received 1,172 restricted shares of common stock on 06/18/2025 at no cost. The grant will vest in full on 06/18/2026. Following the award, Lopez directly owns 4,538 shares of ADUS. No sales, options exercises, or cash transactions were disclosed.
This filing reflects routine board equity compensation and does not signal any change in the company’s financial condition, operations, or strategic direction.
Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) is offering unsecured Medium-Term Senior Notes linked to the S&P 500 Futures Excess Return Index, maturing on August 5, 2030. The $1,000-denominated notes pay no periodic interest; instead, investors receive at maturity (i) the full principal and (ii) a positive return only if the index closes above its initial level on the valuation date. Any appreciation will be multiplied by an upside participation rate of at least 120%, providing leveraged exposure to gains. If the index is flat or declines, investors merely receive the $1,000 principal, resulting in zero return.
Key structural terms include: pricing date July 31 2025; issue date August 5 2025; valuation date July 31 2030. The notes are not listed on an exchange and may have limited secondary liquidity. CGMI will act as underwriter, receiving up to $11.30 per note; the issuer’s estimated value is at least $902.50, materially below the $1,000 issue price, reflecting structuring costs and dealer margin.
The underlying index tracks S&P 500 futures, so it lags the total-return S&P 500 by the embedded financing cost and excludes dividends, lowering expected performance relative to equities. Investors also assume (i) credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc., (ii) liquidity risk because the notes are unlisted, and (iii) opportunity cost of forgone dividends and interest. The offering targets investors seeking principal protection at maturity with leveraged upside to equity futures but who are comfortable with the noted structural and credit risks.
- Stated principal: $1,000 per security
- Minimum upside participation: 120%
- No coupons; no dividend entitlement
- Guaranteed by Citigroup Inc.
- CUSIP/ISIN: 17333LFC4 / US17333LFC46
On June 18, 2025, Addus HomeCare Corp. (ADUS) filed a Form 4 reporting that board director Michael Earley was granted 1,172 restricted common shares at a purchase price of $0. The award will vest in full on June 18, 2026. After the grant, Earley now directly owns 11,951 ADUS shares and indirectly controls 2,695 shares through Bird Asset Management, LP, bringing his total beneficial ownership to 14,646 shares. No derivative securities were involved, and the filing does not reference any Rule 10b5-1 trading plan. Because the shares were awarded rather than purchased, the disclosure primarily reflects routine equity compensation intended to align the director’s interests with shareholders and encourage board retention, carrying limited immediate market impact.